Review of immunotherapy innovations for triple-negative breast cancer survival
New Hope for Tough-to-Treat Breast Cancer
This narrative review examines immunotherapy innovations, including immune checkpoint inhibitors and combination strategies, for patients wi…
This approach may change how doctors treat one of the hardest forms of breast cancer.
PARP inhibitors significantly improve progression-free survival in BRCA-mutated ovarian cancer patients.
PARP Drugs Help BRCA Ovarian Cancer Patients Live Longer
This meta-analysis of 12 studies evaluated PARP inhibitor–based therapy in patients with BRCA-mutated ovarian cancer. Results showed a signi…
Women with BRCA-mutated ovarian cancer gain real survival time gains when using PARP inhibitors to delay cancer growth and stay cancer-free …
Precision oncology enables targeted therapies for gynecologic cancers, though acquired resistance remains a barrier.
Precision oncology advances gynecologic cancer care but resistance remains a major barrier
This systematic review examined the current landscape of precision oncology for patients with endometrial, ovarian, and cervical carcinomas.…
Molecular reclassification lets doctors use targeted drugs effectively for gynecologic cancers, but tumor evolution creates a major barrier …